<HTML lang="en" dir="ltr" class="client-nojs">
<style type="text/css">
A:before { content:' '; } 
A:after { content:' '; } 
SPAN:before { content:' '; } 
SPAN:after { content:' '; } 
</style>
<BODY class="mediawiki ltr sitedir-ltr ns-0 ns-subject page-Team_SDU-Denmark_Entrepreneurship skin-igem action-view"><DIV id="globalWrapper"><DIV id="content" class="mw-body" role="main"><H1 id="firstHeading" class="firstHeading"><SPAN dir="auto">Team:SDU-Denmark/Entrepreneurship</SPAN></H1><DIV id="bodyContent"><DIV id="mw-content-text" lang="en" dir="ltr" class="mw-content-ltr"><DIV class="BackgroundLayout"><DIV class="top bannerShadow"><DIV class="NavbarContainer"><DIV class="NavbarContainerInner"><DIV class="MenuButton" id="btnWelcome"><A class="MenuButtonLink" href="https://2015.igem.org/Team:SDU-Denmark">Welcome</A></DIV><DIV class="MenuButton" id="btnTour"><A class="MenuButtonLink" href="https://2015.igem.org/Team:SDU-Denmark/Tour10">Interactive wiki-tour</A></DIV><DIV class="MenuButton" id="btnMenu"><A class="MenuButtonLink" href="#" id="btnMenu2">Menu</A><DIV class="menuPopup"><DIV class="menuPopupContent"><DIV class="menuPopupContentInner bannerShadow"><DIV class="menuIntro"><DIV class="warningBox"><P class="menuIntro">
You really should try our <A href="https://2015.igem.org/Team:SDU-Denmark/Tour10">interactive wiki tour</A> instead! 

</P></DIV><P class="menuIntro">
But if you are looking for a specific page - you are in the right place. 
</P><DIV class="menuItems"><UL><LI class="header"><A href="https://2015.igem.org/Team:SDU-Denmark/Tour10">Introduction</A></LI><LI><A href="https://2015.igem.org/Team:SDU-Denmark/Tour11">The Team</A></LI><LI><A href="https://2015.igem.org/Team:SDU-Denmark/Tour12">Attributions</A></LI><LI><A href="https://2015.igem.org/Team:SDU-Denmark/Tour13">Gallery</A></LI><LI><A href="https://2015.igem.org/Team:SDU-Denmark/Tour14">Medal Requirements</A></LI></UL><UL><LI class="header"><A href="https://2015.igem.org/Team:SDU-Denmark/Tour20"> Antibody Issue</A></LI><LI><A href="https://2015.igem.org/Team:SDU-Denmark/Tour21">Antibody Production</A></LI><LI><A href="https://2015.igem.org/Team:SDU-Denmark/Tour22">Animal Ethics</A></LI><LI><A href="https://2015.igem.org/Team:SDU-Denmark/Tour23">The Alternative</A></LI></UL><UL><LI class="header"><A href="https://2015.igem.org/Team:SDU-Denmark/Tour30">PAST</A></LI><LI><A href="https://2015.igem.org/Team:SDU-Denmark/Tour31">Two-Hybrid Screening</A></LI><LI><A href="https://2015.igem.org/Team:SDU-Denmark/Tour32">System Design</A></LI><LI><A href="https://2015.igem.org/Team:SDU-Denmark/Tour33">Business</A></LI><LI><A href="https://2015.igem.org/Team:SDU-Denmark/Tour34">Entrepreneurship</A></LI></UL><UL><LI class="header"><A href="https://2015.igem.org/Team:SDU-Denmark/Tour40">Process</A></LI><LI><A href="https://2015.igem.org/Team:SDU-Denmark/Tour41">Complete Journal</A></LI><LI><A href="https://2015.igem.org/Team:SDU-Denmark/Tour42">Collaborations</A></LI><LI><A href="https://2015.igem.org/Team:SDU-Denmark/Tour43">SOPs</A></LI><LI><A href="https://2015.igem.org/Team:SDU-Denmark/Tour44">Safety</A></LI></UL><UL><LI class="header"><A href="https://2015.igem.org/Team:SDU-Denmark/Tour50">Results</A></LI><LI><A href="https://2015.igem.org/Team:SDU-Denmark/Tour51">Characterization</A></LI><LI><A href="https://2015.igem.org/Team:SDU-Denmark/Tour52">Two-Hybrid System</A></LI><LI><A href="https://2015.igem.org/Team:SDU-Denmark/Tour53">Submitted Parts</A></LI><LI><A href="https://2015.igem.org/Team:SDU-Denmark/Tour54">Interlab Study</A></LI></UL><UL><LI class="header"><A href="https://2015.igem.org/Team:SDU-Denmark/Tour60">Practices</A></LI><LI><A href="https://2015.igem.org/Team:SDU-Denmark/Tour61">Survey</A></LI><LI><A href="https://2015.igem.org/Team:SDU-Denmark/Tour62">Education</A></LI><LI><A href="https://2015.igem.org/Team:SDU-Denmark/Tour63">Ethics</A></LI><LI><A href="https://2015.igem.org/Team:SDU-Denmark/Tour64">A Children's Book</A></LI></UL><UL><LI class="header"><A href="https://2015.igem.org/Team:SDU-Denmark/Tour70">
What is Next?</A></LI><LI><A href="https://2015.igem.org/Team:SDU-Denmark/Tour71">Challenges and Limitations</A></LI><LI><A href="https://2015.igem.org/Team:SDU-Denmark/Tour72">Medical Aspects</A></LI><LI><A href="https://2015.igem.org/Team:SDU-Denmark/Tour72">Lab Work</A></LI><LI><A href="https://2015.igem.org/Team:SDU-Denmark/Tour73">The End</A></LI></UL></DIV></DIV></DIV></DIV></DIV></DIV></DIV></DIV></DIV><DIV class="tourBoundingBox"><DIV class="tourBoundingBoxInner bannerShadow"><DIV class="parentTourItem "><A class="tourItemLabel" title="Get a brief overview of the project.">
                Introduction
            </A></DIV><DIV class="expandedTour" style="display:none"><DIV class="expandedTourInner"><DIV class="parentTourItem"><A class="tourItemLabel" title="Would you like to meet our team?">
                       The Team
                    </A></DIV><DIV class="parentTourItem"><A class="tourItemLabel" title="To express our thankfulness.">
                        Attributions
                    </A></DIV><DIV class="parentTourItem"><A class="tourItemLabel" title="">
                        Gallery
                    </A></DIV><DIV class="parentTourItem"><A class="tourItemLabel" title="">
                        Medal Requirements
                    </A></DIV></DIV></DIV><DIV class="parentTourItem "><A class="tourItemLabel" title="">
               Antibody issue
            </A></DIV><DIV class="expandedTour" style="display:none"><DIV class="expandedTourInner"><DIV class="parentTourItem"><A class="tourItemLabel" title="">
                       Antibody production
                    </A></DIV><DIV class="parentTourItem"><A class="tourItemLabel" title="">
                        Animal Ethics
                    </A></DIV><DIV class="parentTourItem"><A class="tourItemLabel" title="">
                        The Alternative
                    </A></DIV></DIV></DIV><DIV class="parentTourItem "><A class="tourItemLabel" title="">
                PAST            </A></DIV><DIV class="expandedTour" style="display:none"><DIV class="expandedTourInner"><DIV class="parentTourItem"><A class="tourItemLabel" title="">
                        Two-Hybrid Screening
                    </A></DIV><DIV class="parentTourItem"><A class="tourItemLabel" title="">
                        System Design
                    </A></DIV><DIV class="parentTourItem"><A class="tourItemLabel" title="">
                        Business
                    </A></DIV><DIV class="parentTourItem"><A class="tourItemLabel" title="">
                       Entrepreneurship
                    </A></DIV></DIV></DIV><DIV class="parentTourItem "><A class="tourItemLabel" title="">
                Process
            </A></DIV><DIV class="expandedTour" style="display:none"><DIV class="expandedTourInner"><DIV class="parentTourItem"><A class="tourItemLabel" title="">
                        Complete Journal
                    </A></DIV><DIV class="parentTourItem"><A class="tourItemLabel" title="">
                        Collaborations
                    </A></DIV><DIV class="parentTourItem"><A class="tourItemLabel" title="">
                       SOPs
                    </A></DIV><DIV class="parentTourItem"><A class="tourItemLabel" title="">
                        Safety
                    </A></DIV></DIV></DIV><DIV class="parentTourItem "><A class="tourItemLabel" title="">
               Results
            </A></DIV><DIV class="expandedTour" style="display:none"><DIV class="expandedTourInner"><DIV class="parentTourItem"><A class="tourItemLabel" title="">
                        Characterization
                    </A></DIV><DIV class="parentTourItem"><A class="tourItemLabel" title="">
                      Two-Hybrid System
                    </A></DIV><DIV class="parentTourItem"><A class="tourItemLabel" title="">
                       Submitted Parts
                    </A></DIV><DIV class="parentTourItem"><A class="tourItemLabel" title="">
                        Interlab Study
                    </A></DIV></DIV></DIV><DIV class="parentTourItem "><A class="tourItemLabel" title="">
Practices
            </A></DIV><DIV class="expandedTour" style="display:none"><DIV class="expandedTourInner"><DIV class="parentTourItem"><A class="tourItemLabel" title="">
                        Survey
                    </A></DIV><DIV class="parentTourItem"><A class="tourItemLabel" title="">
                        Education
                    </A></DIV><DIV class="parentTourItem"><A class="tourItemLabel" title="">
                        Ethics
                    </A></DIV><DIV class="parentTourItem"><A class="tourItemLabel" title="">
                       A Childrenâ€™s Book
                    </A></DIV></DIV></DIV><DIV class="parentTourItem "><A class="tourItemLabel" title="">
               What is Next
            </A></DIV><DIV class="expandedTour" style="display:none"><DIV class="expandedTourInner"><DIV class="parentTourItem"><A class="tourItemLabel" title="">
                        Challenges and Limitations
                    </A></DIV><DIV class="parentTourItem"><A class="tourItemLabel" title="">
                        Medical Aspects
                    </A></DIV><DIV class="parentTourItem"><A class="tourItemLabel" title="">
                        Lab Work
                    </A></DIV><DIV class="parentTourItem"><A class="tourItemLabel" title="">
                      The End
                    </A></DIV></DIV></DIV></DIV></DIV><DIV class="MainLayout"><DIV class="content"><DIV class="memberWrapper"><P><I> &quot;Design is not just what it looks like and feels like. Design is how it works.&quot; - <B>Steve Jobs</B></I></P><H1 align="center">Entrepreneurship</H1><DIV class="thumb tright"><DIV class="thumbinner" style="width:315px; height:235px;"><DIV class="thumbcaption"> Figure 1: Process Flow Diagram (PFD)  </DIV></DIV></DIV><P><SPAN class="intro">We as a team</SPAN> has decided to enter the manufacturing track. This was due to our excitement of the applicability of our project. We feel strongly, that the need of a replacement for mAbs and not least the opportunity to reduce usage of laboratory animals, should be explored on an industrial level.
</P><P><SPAN class="intro">The aim</SPAN> of PAST is to cater to customers with very specific needs. Therefore it has been decided to design several small-scale operations, which will allow the company to efficiently fill changing orders without accumulating large stocks. 
It has not been possible to determine any values for the process design experimentally, therefore estimates has been made using data obtained on proteins considered to be as close in properties as possible to the peptide aptamers. Protocols and research papers have been extrapolated linearly, which is most often not possible. Therefore experiments should be conducted on both laboratory and pilot scale, and this proposal should only be taken as an indicator of the feasibility and competitiveness of the operation, and thereby the validity of carrying out the necessary experiments. 
Below is our process design. Click the boxes to dig deeper into each section. </P><DIV class="accordion" style="width:100%;"><DIV class="accordionTitel"> A1: Autoclave  </DIV><DIV class="pane" style="height:auto;"><DIV class="thumb tright"><DIV class="thumbinner" style="width:455px; height:190px;"><DIV class="thumbcaption">Figure 2: Autoclave A1 </DIV></DIV></DIV><SPAN class="intro">Before the fermentation</SPAN> can begin, the substrate must be sterilized to avoid contamination of the 

fermentation broth. For this procedure a batch 

sterilization has been chosen. To ensure sterility the feed is heated to 121 [Â°C], the pressure set at 2 [bar] and the 

residence time at 30 <SPAN class="sourceReference">[min]</SPAN>. 
<SPAN class="tooltip"><SPAN class="tooltipHeader">Reference:</SPAN>
Michael L. Shuler and Fikret Kargi. Bioprocess Engineering - Basic Concepts; second edition; Pearson Education International; 2002
</SPAN> This was simulated in Aspen Plus using the BK10 method, and only the 

compounds available in the database were considered. The simulation showed a volume of the autoclave of 

26.6 [L] and a heat duty of 48,483 [kJ/batch]. The substrate consist of Water (H<SUB>2</SUB>O), Glucose, 

Ammonium chloride (NH<SUB>4</SUB>Cl), Monopotassium phosphate (KH<SUB>2</SUB>PO<SUB>4</SUB>), Epsom salt (MgSÂ·7 H<SUB>2</SUB>O), Calcium chloride dihydrate (CaCl<SUB>2</SUB>Â·2H<SUB>2</SUB>O), 

Ironsulphate (FeSO<SUB>4</SUB>), L-arganineÂ·HCl, tracemetals and Ampicilin, the composition can be seen in table 1. The 

amount and composition of the substrate was based on a research artic <SPAN class="sourceReference">le.</SPAN>. 
<SPAN class="tooltip"><SPAN class="tooltipHeader">Reference:</SPAN>
L. Yee and H. W. Blanch. Recombinant Trypsin Production in High Cell Density Fed-Batch Cultures in Escherichia coli. Biotechnology and Bioengineering. 1993; 41: 781-790
</SPAN><TABLE class="wikitable" style="width:70%"><CAPTION><B>Table 1:</B> Composition and conditions for A1</CAPTION><TBODY><TR><TD> S1: Feed 1</TD><TD> S2: Feed 1</TD></TR><TR><TD>Total mass [kg]</TD><TD> 24.04</TD><TD> 24.04 </TD></TR><TR><TD>Temperature [Â°C]</TD><TD> 21 </TD><TD>121 </TD></TR><TR><TD>Pressure [bar]</TD><TD> 1 </TD><TD>2 </TD></TR><TR><TD>WT% H<SUB>2</SUB>O</TD><TD>87.53 </TD><TD>87.53 </TD></TR><TR><TD>WT% Glucose</TD><TD> 2.00 </TD><TD>2.00 </TD></TR><TR><TD>WT% NH<SUB>4</SUB>Cl</TD><TD>0.13 </TD><TD>0.13 </TD></TR><TR><TD>WT% KH<SUB>2</SUB>PO<SUB>4</SUB></TD><TD>1.50 </TD><TD>1.50 </TD></TR><TR><TD>WT% MgSÂ·7 H<SUB>2</SUB>O</TD><TD>0.01 </TD><TD>0.01 </TD></TR><TR><TD>WT% CaCl<SUB>2</SUB>Â·2H<SUB>2</SUB>O </TD><TD>0.01 </TD><TD>0.01 </TD></TR><TR><TD>WT% FeSO<SUB>4</SUB></TD><TD>0.01 </TD><TD>0.01 </TD></TR><TR><TD>WT% L-arginineÂ·HCI </TD><TD>0.80 </TD><TD>0.80 </TD></TR><TR><TD>WT% TraceMetals</TD><TD> 8.00 </TD><TD>8.00 </TD></TR><TR><TD>WT% Ampicilin </TD><TD>0.01 </TD><TD>0.01</TD></TR></TBODY></TABLE></DIV><DIV class="accordionTitel"> E1: Heat exchanger </DIV><DIV class="pane" style="height:auto;"><DIV class="thumb tright"><DIV class="thumbinner" style="width:255px; height:150px;"><DIV class="thumbcaption">Figure 3: Heat exchanger E1  </DIV></DIV></DIV><P>
To avoid a flash occurring in the fermenter and ensure the survivel of cells, the substrate has to be cooled to 37 .<SPAN class="sourceReference">[Â°C]</SPAN>. 
<SPAN class="tooltip"><SPAN class="tooltipHeader">Reference:</SPAN>
L. Yee and H. W. Blanch. Recombinant Trypsin Production in High Cell Density Fed-Batch Cultures in Escherichia coli. Biotechnology and Bioengineering. 1993; 41: 781-790
</SPAN> It has been chosen to grow the cells at 

this temperature, though growth at lower temperatures have been shown to decrease the amount of 

inclusion bodies formed. It has to be investigated at a later point if lower temperatures and the following 

prolongation of cycle time, could lead to an increase in product<SPAN class="sourceReference">ion</SPAN>. 
<SPAN class="tooltip"><SPAN class="tooltipHeader">Reference:</SPAN>
Jeffrey Fu, David B. Wilson and Michael L. Shuler. Continuous, High Level Production and Excretion of a Plasmid-Encoded Protein by Escherichia coli in a Two-Stage Chemostat. Biotechnology and Bioengineering, 1993; 41: 937-946
</SPAN> As in A1 a simulation was run in 

Aspen Plus, the results showed the use of cooling water to be 5,474 [L/batch], and a heat duty of 

15,196,014 [kJ/batch].

</P><P><TABLE class="wikitable" style="width:66%;"><CAPTION><B>Table 2:</B> Composition and conditions for E1</CAPTION><TBODY><TR><TD> S1: Feed 1</TD><TD> S2: Feed 1</TD></TR><TR><TD>Total mass [kg]</TD><TD> 24.04</TD><TD> 24.04 </TD></TR><TR><TD>Temperature [Â°C]</TD><TD> 21 </TD><TD>121 </TD></TR><TR><TD>Pressure [bar]</TD><TD> 1 </TD><TD>2 </TD></TR><TR><TD>WT% H<SUB>2</SUB>O </TD><TD>87.53 </TD><TD>87.53 </TD></TR><TR><TD>WT% Glucose</TD><TD> 2.00 </TD><TD>2.00 </TD></TR><TR><TD>WT% NH<SUB>4</SUB>Cl</TD><TD>0.13 </TD><TD>0.13 </TD></TR><TR><TD>WT% KH<SUB>2</SUB>PO<SUB>4</SUB></TD><TD>1.50 </TD><TD>1.50 </TD></TR><TR><TD>WT% MgSÂ·7 H<SUB>2</SUB>O</TD><TD>0.01 </TD><TD>0.01 </TD></TR><TR><TD>WT% CaCl<SUB>2</SUB>Â·2H<SUB>2</SUB>O</TD><TD>0.01 </TD><TD>0.01 </TD></TR><TR><TD>WT% FeSO<SUB>4</SUB></TD><TD>0.01 </TD><TD>0.01 </TD></TR><TR><TD>WT% L-arginineÂ·HCI </TD><TD>0.80 </TD><TD>0.80 </TD></TR><TR><TD>WT% TraceMetals</TD><TD> 8.00 </TD><TD>8.00 </TD></TR><TR><TD>WT% Ampicilin </TD><TD>0.01 </TD><TD>0.01</TD></TR></TBODY></TABLE></P></DIV><DIV class="accordionTitel"> R1.1: Batch fermentation</DIV><DIV class="pane" style="height:auto;"><DIV class="thumb tright"><DIV class="thumbinner" style="width:255px; height:450px;"><DIV class="thumbcaption">Figure 4: Batch fermentation  </DIV></DIV></DIV><DIV class="thumb tright"><DIV class="thumbinner" style="width:255px; height:290px;"><DIV class="thumbcaption"> Figure 5: Illustration of the scale up proce <SPAN class="sourceReference">ss</SPAN>. 
<SPAN class="tooltip"><SPAN class="tooltipHeader">Reference:</SPAN>
L. Yee and H. W. Blanch. Recombinant Trypsin Production in High Cell Density Fed-Batch Cultures in Escherichia coli. Biotechnology and Bioengineering. 1993; 41: 781-790
</SPAN></DIV></DIV></DIV>

Fermentation is carried out under two conditions. In this first phase growth is carried out as a batch until

glucose is depleted, and will take approximately 13 [h]. After which, cells will be grown to high densities in a 

fed-batch. One hindrance for accumulation of high biomass concentrations is the formation of inhibitors as 

acetate. By restricting the carbon source this formation can be reduced greatly, which can be viewed in 

figure 5. The figure describes the experimental results presented in the research paper used for estimates. 

The inoculum is scale linearly as in the case of the substrate. Therefore the same cell concentration is kept 

and the time will not be affected. The fed-batch and induction will be discussed further bel<SPAN class="sourceReference">ow</SPAN>. 
<SPAN class="tooltip"><SPAN class="tooltipHeader">Reference:</SPAN>
L. Yee and H. W. Blanch. Recombinant Trypsin Production in High Cell Density Fed-Batch Cultures in Escherichia coli. Biotechnology and Bioengineering. 1993; 41: 781-790
</SPAN><TABLE class="wikitable" style="width:60%;"><CAPTION><B>Table 3:</B> Composition and conditions for E1.1</CAPTION><TBODY><TR><TD>S3: Feed 1</TD><TD> S4: innoculum</TD><TD> R1: first phase </TD></TR><TR><TD>Total mass [kg] </TD><TD>24.04</TD><TD> 1.72</TD><TD> 25.76 </TD></TR><TR><TD>Temperature [Â°C] </TD><TD>37 </TD><TD>21 </TD><TD>37 </TD></TR><TR><TD>Pressure [bar] </TD><TD>1 </TD><TD>1 </TD><TD>1 </TD></TR><TR><TD>WT% Dry cells</TD><TD> 0.03</TD><TD> 0.70 </TD></TR><TR><TD>WT% H<SUB>2</SUB>O</TD><TD>87.53 </TD><TD>87.50</TD><TD> 88.84 </TD></TR><TR><TD>WT% Glucose </TD><TD>2.00</TD><TD> 2.00 </TD></TR><TR><TD>WT% NH<SUB>4</SUB>Cl</TD><TD>0.13</TD><TD> 0.13</TD><TD> 0.13 </TD></TR><TR><TD>WT% KH<SUB>2</SUB>PO<SUB>4</SUB></TD><TD>1.50</TD><TD> 1.50 </TD><TD>1.50 </TD></TR><TR><TD>WT% MgSÂ·7 H<SUB>2</SUB>O</TD><TD>0.01 </TD><TD>0.01 </TD><TD>0.01 </TD></TR><TR><TD>WT% CaCl<SUB>2</SUB>Â·2H<SUB>2</SUB>O</TD><TD>0.01 </TD><TD>0.01 </TD><TD>0.01 </TD></TR><TR><TD>WT% FeSO<SUB>4</SUB></TD><TD>0.01 </TD><TD>0.01 </TD><TD>0.01 </TD></TR><TR><TD>WT% L-arginineÂ·HCI </TD><TD>0.80</TD><TD> 0.80 </TD><TD>0.80 </TD></TR><TR><TD>WT% TraceMetals </TD><TD>8.00 </TD><TD>8.00</TD><TD> 7.99 </TD></TR><TR><TD>WT% Ampicilin </TD><TD>0.01</TD><TD> 0.01 </TD><TD>0.005</TD></TR></TBODY></TABLE></DIV><DIV class="accordionTitel"> A2: Autoclave  </DIV><DIV class="pane" style="height:auto;"><DIV class="thumb tright"><DIV class="thumbinner" style="width:255px; height:130px;"><DIV class="thumbcaption">Figure 6: Autoclave A2 </DIV></DIV></DIV><P>
The substrate used for the fed-batch phase of the fermentation is sterilized in A2.  The same type of 

sterilization and conditions as in the A1 are chosen. Simulation in Aspen Plus 

yielded a volume of  16.2 [L] and a heat duty of 7.457 [kJ/batch]. The composition of the 

substrate can be viewed in table 4. It should be noted that in order to avoid

dilution of the cell concentration, the concentration of glucose is considerably 

higher than in <SPAN class="sourceReference">S1.</SPAN>. 
<SPAN class="tooltip"><SPAN class="tooltipHeader">Reference:</SPAN>
L. Yee and H. W. Blanch. Recombinant Trypsin Production in High Cell Density Fed-Batch Cultures in Escherichia coli. Biotechnology and Bioengineering. 1993; 41: 781-790
</SPAN><TABLE class="wikitable" style="width:63%;"><CAPTION><B>Table 4:</B> Composition and conditions for A2 </CAPTION><TBODY><TR><TD>S5: Feed 2</TD><TD> S6: Feed 2</TD></TR><TR><TD>Total mass [kg] </TD><TD>18.89</TD><TD> 18.89 </TD></TR><TR><TD>Temperature [Â°C] </TD><TD>21 </TD><TD>121 </TD></TR><TR><TD>Pressure [bar] </TD><TD>1 </TD><TD>2 </TD></TR><TR><TD>WT% H<SUB>2</SUB>O</TD><TD>30.54 </TD><TD>30.54 </TD></TR><TR><TD>WT% Glucose </TD><TD>65.00 </TD><TD>65.00 </TD></TR><TR><TD>WT% NH<SUB>4</SUB>Cl</TD><TD>0.50 </TD><TD>0.50 </TD></TR><TR><TD>WT% KH<SUB>2</SUB>PO<SUB>4</SUB></TD><TD>0.17 </TD><TD>0.17 </TD></TR><TR><TD>WT% MgSÂ·7 H<SUB>2</SUB>O</TD><TD>0.75 </TD><TD>0.75 </TD></TR><TR><TD>WT% L-arginineÂ·HCI </TD><TD>3.00 </TD><TD>3.00 </TD></TR><TR><TD>WT% Ampicilin </TD><TD>0.04</TD><TD> 0.04</TD></TR></TBODY></TABLE></P></DIV><DIV class="accordionTitel">E2: Heat exchanger </DIV><DIV class="pane" style="height:auto;"><DIV class="thumb tright"><DIV class="thumbinner" style="width:255px; height:170px;"><DIV class="thumbcaption">Figure 7: Heat exchanger E2 </DIV></DIV></DIV>

The substrate of the fed-batch has to be cooled as in the case of E1. The same conditions are chosen, see 

table 5, and the exchanger was simulated in Aspen Plus. The simulation showed that 348 [L/batch] cooling 

water is needed, and that the heat duty is 4,016,502 [kJ/batch]. 


<TABLE class="wikitable" style="width:60%;"><CAPTION><B>Table 5:</B> Composition and conditions for E1  </CAPTION><TBODY><TR><TD>S6: Feed 2</TD><TD> S7: Feed 2 </TD></TR><TR><TD>Total mass [kg] </TD><TD>18.89 </TD><TD>18.89 </TD></TR><TR><TD>Temperature [Â°C] </TD><TD>121 </TD><TD>37 </TD></TR><TR><TD>Pressure [bar]</TD><TD> 2</TD><TD> 1 </TD></TR><TR><TD>WT% H<SUB>2</SUB>O</TD><TD>30.54</TD><TD> 30.54 </TD></TR><TR><TD>WT% Glucose </TD><TD>65.00</TD><TD> 65.00 </TD></TR><TR><TD>WT% NH<SUB>4</SUB>Cl</TD><TD>0.50 </TD><TD>0.50 </TD></TR><TR><TD>WT% KH<SUB>2</SUB>PO<SUB>4</SUB></TD><TD>0.17 </TD><TD>0.17 </TD></TR><TR><TD>WT% MgSÂ·7 H<SUB>2</SUB>O</TD><TD>0.75</TD><TD> 0.75 </TD></TR><TR><TD>WT% L-arginineÂ·HCI </TD><TD>3.00</TD><TD> 3.00 </TD></TR><TR><TD>WT% Ampicilin </TD><TD>0.04 </TD><TD>0.04</TD></TR></TBODY></TABLE></DIV><DIV class="accordionTitel">R1.2: Fed-batch fermentation  </DIV><DIV class="pane" style="height:auto;"><DIV class="thumb tright"><DIV class="thumbinner" style="width:255px; height:430px;"><DIV class="thumbcaption">Figure 8: Fed-batch fermentation</DIV></DIV></DIV>
As mentioned above, the fed-batch facilitate high yield of dry cells. The experimental data from the research

paper showed that a concentration of 75 [g dry cells/L] was reached after 27 [h]. This was deemed an 

appropriate level to start induction. The results also showed that substrate was fed in a rate, where 

glucose did not accumulate in the broth, and furthermore that the levels of acetate after an initial rise was non-

existent in the end of the fed-batch phase, see figure 5: Batch fermentation. The composition of 

the fermentation broth before induction can be viewed in <SPAN class="sourceReference">table 6</SPAN>. 
<SPAN class="tooltip"><SPAN class="tooltipHeader">Reference:</SPAN>
L. Yee and H. W. Blanch. Recombinant Trypsin Production in High Cell Density Fed-Batch Cultures in Escherichia coli. Biotechnology and Bioengineering. 1993; 41: 781-790


Michael L. Shuler and Fikret Kargi. Bioprocess Engineering - Basic Concepts; second edition; Pearson Education International; 2002
</SPAN><TABLE class="wikitable" style="width:60%;"><CAPTION><B>Table 6:</B> Composition and conditions for R1.2  </CAPTION><TBODY><TR><TD>S7: Feed 2</TD><TD> R1: Second phase </TD></TR><TR><TD>Total mass [kg] </TD><TD>18.89</TD><TD> 44.65 </TD></TR><TR><TD>Temperature [Â°C] </TD><TD>37 </TD><TD>37 </TD></TR><TR><TD>Pressure [bar] </TD><TD>1 </TD><TD>1 </TD></TR><TR><TD>WT% Dry cells</TD><TD> 7.50 </TD></TR><TR><TD>WT% H<SUB>2</SUB>O</TD><TD>30.54 </TD><TD>84.59 </TD></TR><TR><TD>WT% Glucose </TD><TD>65.00 </TD></TR><TR><TD>WT% NH<SUB>4</SUB>Cl</TD><TD>0.50 </TD><TD>0.29 </TD></TR><TR><TD>WT% KH<SUB>2</SUB>PO<SUB>4</SUB></TD><TD> 0.17</TD><TD> 0.94 </TD></TR><TR><TD>WT% MgSÂ·7 H<SUB>2</SUB>O</TD><TD> 0.75 </TD><TD>0.32 </TD></TR><TR><TD>WT% CaCl<SUB>2</SUB>Â·2H<SUB>2</SUB>O</TD><TD>0.004 </TD></TR><TR><TD>WT% FeSO<SUB>4</SUB></TD><TD>0.01 </TD></TR><TR><TD>WT% L-arginineÂ·HCI </TD><TD>3.00 </TD><TD>1.73 </TD></TR><TR><TD>WT% TraceMetals </TD><TD>4.61 </TD></TR><TR><TD>WT% Ampicilin </TD><TD>0.04 </TD><TD>0.02</TD></TR></TBODY></TABLE></DIV><DIV class="accordionTitel">R1.3: Induction   </DIV><DIV class="pane" style="height:auto;"><DIV class="thumb tright"><DIV class="thumbinner" style="width:255px; height:425px;"><DIV class="thumbcaption">Figure 9: Induction</DIV></DIV></DIV>

Now the production of peptide aptamers can begin. The production is induced by Isopropyl-Î²-D-

thiogalactoside (IPTG), which is added to a concentration of 2 [mM]. The target concentration of product will be discussed during the 

elution phase of the product recovery. The composition at start of induction and of the fermentation broth 

can be viewed in table 7. It was shown that inducing in the late log phase let to

high yields of production, reducing the production phase to 4 [h]. Another benefit of the shortened residence time of the product, which reduces the risk of degradation by for example proteases. In the research paper the yield of product was reported to be 

56 [mg/L] and the dry cell concentration was 92 <SPAN class="sourceReference">[g/L]</SPAN>. 
<SPAN class="tooltip"><SPAN class="tooltipHeader">Reference:</SPAN>
L. Yee and H. W. Blanch. Recombinant Trypsin Production in High Cell Density Fed-Batch Cultures in Escherichia coli. Biotechnology and Bioengineering. 1993; 41: 781-790


Michael L. Shuler and Fikret Kargi. Bioprocess Engineering - Basic Concepts; second edition; Pearson Education International; 2002
</SPAN><TABLE class="wikitable" style="width:60%;"><CAPTION><B>Table 7:</B> Composition and conditions for R1.3  </CAPTION><TBODY><TR><TD>R1: induction start</TD><TD> S8: Fermentation broth</TD></TR><TR><TD>Total mass [kg]</TD><TD> 44.64 </TD><TD>44.64 </TD></TR><TR><TD>Temperature [Â°C]</TD><TD>  37 </TD><TD> 37 </TD></TR><TR><TD>Pressure [bar] </TD><TD> 1 </TD><TD> 1 </TD></TR><TR><TD>WT% Peptide aptamer </TD><TD> 0.01</TD></TR><TR><TD>WT% Dry cells</TD><TD>  7.50 </TD><TD> 9.20 </TD></TR><TR><TD>WT% H<SUB>2</SUB>O</TD><TD> 84.54</TD><TD>  82.89 </TD></TR><TR><TD>WT% NH<SUB>4</SUB>Cl</TD><TD> 0.29 </TD><TD> 0.29 </TD></TR><TR><TD>WT% KH<SUB>2</SUB>PO<SUB>4</SUB></TD><TD> 0.94 </TD><TD> 0.94 </TD></TR><TR><TD>WT% MgSÂ·7 H<SUB>2</SUB>O</TD><TD> 0.32 </TD><TD> 0.32 </TD></TR><TR><TD>WT% CaCl<SUB>2</SUB>Â·2H<SUB>2</SUB>O</TD><TD> 0.004</TD><TD>  0.004 </TD></TR><TR><TD>WT% FeSO<SUB>4</SUB></TD><TD> 0.01 </TD><TD> 0.01 </TD></TR><TR><TD>WT% L-arginineÂ·HCI </TD><TD> 1.73 </TD><TD> 1.73 </TD></TR><TR><TD>WT% TraceMetals </TD><TD> 4.61</TD><TD>  4.60 </TD></TR><TR><TD>WT% Ampicilin </TD><TD> 0.02</TD><TD>  0.02 </TD></TR><TR><TD>WT% IPTG </TD><TD> 0.05 </TD></TR></TBODY></TABLE></DIV><DIV class="accordionTitel">C1.1: Equilibration   </DIV><DIV class="pane" style="height:auto;"><DIV class="thumb tright"><DIV class="thumbinner" style="width:235px; height:620px;"><DIV class="thumbcaption"> Figure 10: Equilibration of C1</DIV></DIV></DIV>

This is the first step of the product recovery. Before applying the fermentation broth to the column it needs

to be fluidized. The fluidization process is described in greater detail during the next step. An important 

parameter for the creation of a stable bed is viscosity, should viscosities of the different buffers used vary 

in a degree that destabilizes the bed an inert viscous liquid will be add<SPAN class="sourceReference">ed.</SPAN>. 
<SPAN class="tooltip"><SPAN class="tooltipHeader">Reference:</SPAN>
Pharmacia. Introduction to Expanded Bed Adsorption. 
<A target="_blank" href="http://wolfson.huji.ac.il/purification/PDF/Expanded_Bed_Absorption/PHARMACIA_IntrodEBA.pdf">(Link)</A> Accessed July 18<SUP>th</SUP> 2015]
</SPAN><P>
The expansion is achieved be applying 10 bed volumes (BV) of column buffer (20 mM (4-(2-

Hydroxyethyl)piperazine-1-ethanesulfonic acid sodium salt) (Na-HEPES) and 500 mM Sodium chloride 

(NaCl)) at a flowrate of 300 [cm/h], which is recommended, though flows between 200 and 400 [cm/h] has been shown 

sufficient. The composition can be viewed in 

table 8. Determination of the BV relies on the production (see

equation 1), it has been decided to produce 2 [g/batch] of the peptide aptamer. This decision will be 

elaborated in the decription of the elution step 
 <SPAN class="sourceReference">(C1.4).</SPAN><SPAN class="tooltip"><SPAN class="tooltipHeader">Reference:</SPAN>
NEB-impact 

Pharmacia. Introduction to Expanded Bed Adsorption. 
<A target="_blank" href="http://wolfson.huji.ac.il/purification/PDF/Expanded_Bed_Absorption/PHARMACIA_IntrodEBA.pdf">(Link)</A> Accessed July 18<SUP>th</SUP> 2015]
</SPAN></P><P>
BV [L]=(binding capacity of the beads [g/L])/(mass of product [g] ) = 1.19 L	(1)
</P><P>
To estimate the time needed for equilibration, we need to estimate the volume of the column. Expansion is 

reported to be 2-3 BV, therefore an expansion of 2.5 BV was chosen for calculations. Thus the column should 

be able to contain approximately 3 L. A column with a diameter of 50 [mm] is deemed to be appropriate for 

this process. To transfer this flowrate to a volumetric, it is calculated how large the volume is per cm, which 

is approximately 0.02[L]. This corresponds to a volumetric flowrate of 6 [L/h]. Now the time of application 

can be calculated to be 2 [h] and the height of the column to be 1.5 <SPAN class="sourceReference">[m]</SPAN>. 
<SPAN class="tooltip"><SPAN class="tooltipHeader">Reference:</SPAN>
NEB-impact 

Pharmacia. Introduction to Expanded Bed Adsorption. 
<A target="_blank" href="http://wolfson.huji.ac.il/purification/PDF/Expanded_Bed_Absorption/PHARMACIA_IntrodEBA.pdf">(Link)</A> Accessed July 18<SUP>th</SUP> 2015]
</SPAN></P><P><TABLE class="wikitable" style="width:62%;"><CAPTION><B>Table 8:</B> Composition and conditions for C1.1  </CAPTION><TBODY><TR><TD>S9: equilibration </TD><TD>S10: Waste </TD></TR><TR><TD>Total mass [kg] </TD><TD>11.88 </TD><TD>11.88 </TD></TR><TR><TD>Temperature [Â°C] </TD><TD>21 </TD><TD>21 </TD></TR><TR><TD>Pressure [bar]</TD><TD> 1 </TD><TD>1 </TD></TR><TR><TD>WT% </TD><TD>96.60 </TD><TD>96.60 </TD></TR><TR><TD>WT% NaHEPES </TD><TD>0.48 </TD><TD>0.48 </TD></TR><TR><TD>WT% NaCl </TD><TD>2.92 </TD><TD>2.92 </TD></TR></TBODY></TABLE></P></DIV><DIV class="accordionTitel">C1.2: Application and wash   </DIV><DIV class="pane" style="height:auto;"><DIV class="thumb tright"><DIV class="thumbinner" style="width:255px; height:640px;"><DIV class="thumbcaption">Figure 11: Application of fermentation broth and wash of C1</DIV></DIV></DIV>

The benefit of the EBA is, that the fluidization leaves space between the beads for particulate matter to

pass through. Rendering the solid separation steps of traditional product recovery unnecessary. 

This type of chromatography has been reported to be a one-step purification. Another benefit is the time reduction before the protein

is bound to the beads, further reducing the residence ti<SPAN class="sourceReference">me.</SPAN>. 
<SPAN class="tooltip"><SPAN class="tooltipHeader">Reference:</SPAN>

Pharmacia. Introduction to Expanded Bed Adsorption. 
<A target="_blank" href="http://wolfson.huji.ac.il/purification/PDF/Expanded_Bed_Absorption/PHARMACIA_IntrodEBA.pdf">(Link)</A> Accessed July 18<SUP>th</SUP> 2015]
</SPAN><P>
The bed is fluidized by controlling the density of the beads, and thereby the downward force of 

sedimentation, and the upward force created by the flow. The sedimentation velocity is controlled by the 

design of the beads. In a stable bed the beads follow a Gaussian distribution. This is obtained by varying the 

density of the beads. Therefore the ordinary agarose beads are fitted with inert cores of varying diameters.
 An unstable bed leads to risk of turbulence or 

channelling, which will say that the feed does not have sufficient contact with the beads to bind the 

peptide aptamers efficien<SPAN class="sourceReference">tly</SPAN>. 
<SPAN class="tooltip"><SPAN class="tooltipHeader">Reference:</SPAN>

Pharmacia. Introduction to Expanded Bed Adsorption. 
<A target="_blank" href="http://wolfson.huji.ac.il/purification/PDF/Expanded_Bed_Absorption/PHARMACIA_IntrodEBA.pdf">(Link)</A> Accessed July 18<SUP>th</SUP> 2015]
</SPAN></P>
In this step the fermentation broth is applied first, after which all impurities are washed out of the column by

applying 20 BV of column buffer. The streams can be viewed in ta<SPAN class="sourceReference">ble 9</SPAN>. 
<SPAN class="tooltip"><SPAN class="tooltipHeader">Reference:</SPAN>

NEB-impact
</SPAN><P><TABLE class="wikitable" style="width:60%;"><CAPTION><B>Table 9:</B> Composition and conditions for C1.2  </CAPTION><TBODY><TR><TD>S8: Fermentation broth</TD><TD> S11: Wash </TD><TD> S12: Waste</TD></TR><TR><TD>Total mass [kg] </TD><TD>44.64</TD><TD> 23.75</TD><TD> 68.39 </TD></TR><TR><TD>Temperature [Â°C] </TD><TD>37 </TD><TD>21 </TD><TD>21 </TD></TR><TR><TD>Pressure [bar]</TD><TD> 1 </TD><TD>1 </TD><TD>1 </TD></TR><TR><TD>WT% Peptide aptamer </TD><TD>0.01</TD></TR><TR><TD>WT% Dry cells </TD><TD>9.20 </TD><TD>6.01 </TD></TR><TR><TD>WT% H<SUB>2</SUB>O</TD><TD>82.89 </TD><TD>96.60 </TD><TD>88.83 </TD></TR><TR><TD>WT% NH<SUB>4</SUB>Cl</TD><TD> 0.29</TD><TD> 0.19 </TD></TR><TR><TD>WT% KH<SUB>2</SUB>PO<SUB>4</SUB></TD><TD>0.94 </TD><TD>0.61 </TD></TR><TR><TD>WT% MgSÂ·7 H<SUB>2</SUB>O</TD><TD>0.32 </TD><TD>0.21 </TD></TR><TR><TD>WT% CaCl<SUB>2</SUB>Â·2H<SUB>2</SUB>O</TD><TD>0.004 </TD><TD>0.0026 </TD></TR><TR><TD>WT% FeSO<SUB>4</SUB></TD><TD>0.01</TD><TD> 0.01 </TD></TR><TR><TD>WT% L-arginineÂ·HCI </TD><TD>1.73</TD><TD> 1.13</TD></TR><TR><TD>WT% TraceMetals </TD><TD>4.60 </TD><TD>3.00 </TD></TR><TR><TD>WT% Ampicilin </TD><TD>0.02 </TD><TD>0.01 </TD></TR><TR><TD>WT% NaHEPES </TD><TD>0.48</TD><TD> 0.17 </TD></TR><TR><TD>WT% NaCl </TD><TD>2.92 </TD><TD>1.01 </TD></TR></TBODY></TABLE></P></DIV><DIV class="accordionTitel">A3: Autoclave   </DIV><DIV class="pane" style="height:auto;"><DIV class="thumb tright"><DIV class="thumbinner" style="width:255px; height:180px;"><DIV class="thumbcaption">Figure 12: Autoclave A3</DIV></DIV></DIV>

 It is assumed that 

all cells will be contained in S10 and S12 and should be sterilized.. The conditions during sterilization is the same as that of the A1 

and A2. The simulation in Aspen Plus yields the following results: a volume of 80.2 [L] and 

a heat duty of 167,301,000 [kJ/batch].
<P><TABLE class="wikitable" style="width:60%;"><CAPTION><B>Table 10:</B> Composition and conditions for A3  </CAPTION><TBODY><TR><TD>S21: Waste</TD><TD> S22: Waste</TD></TR><TR><TD>Total mass [kg] </TD><TD>80.27</TD><TD> 80.27 </TD></TR><TR><TD>Temperature [Â°C] </TD><TD>21 </TD><TD>121 </TD></TR><TR><TD>Pressure [bar] </TD><TD>1 </TD><TD>2 </TD></TR><TR><TD>WT% Dry cells</TD><TD> 5.12 </TD><TD>5.12 </TD></TR><TR><TD>WT% H<SUB>2</SUB>O</TD><TD>89.98 </TD><TD>89.98 </TD></TR><TR><TD>WT% NH<SUB>4</SUB>Cl</TD><TD>0.16</TD><TD> 0.16 </TD></TR><TR><TD>WT% KH<SUB>2</SUB>PO<SUB>4</SUB></TD><TD>0.52 </TD><TD>0.52</TD></TR><TR><TD>WT% MgSÂ·7 H<SUB>2</SUB>O</TD><TD>0.18 </TD><TD>0.18 </TD></TR><TR><TD>WT% CaCl<SUB>2</SUB>Â·2H<SUB>2</SUB>O</TD><TD>0.002 </TD><TD>0.002 </TD></TR><TR><TD>WT% FeSO<SUB>4</SUB></TD><TD>0.005 </TD><TD>0.005 </TD></TR><TR><TD>WT% L-arginineÂ·HCI </TD><TD>0.96 </TD><TD>0.96 </TD></TR><TR><TD>WT% TraceMetals </TD><TD>2.56 </TD><TD>2.56 </TD></TR><TR><TD>WT% Ampicilin </TD><TD>0.01 </TD><TD>0.01 </TD></TR><TR><TD>WT% NaHEPES </TD><TD>0.21 </TD><TD>0.21 </TD></TR><TR><TD>WT% NaCl </TD><TD>1.30 </TD><TD>1.30</TD></TR></TBODY></TABLE></P></DIV><DIV class="accordionTitel">E3: Heat exchanger </DIV><DIV class="pane" style="height:auto;"><DIV class="thumb tright"><DIV class="thumbinner" style="width:255px; height:180px;"><DIV class="thumbcaption">Figure 13: Heat exchanger E3</DIV></DIV></DIV>
Before releasing the waste stream to the ordinary waste water system, the pressure has to be lowered. 

Therefore the stream is cooled to ensure that the waste leaves as a liquid. This unit was simulated in 

Aspen Plus, the results are as follows: 14,854 [L/batch] cooling water is needed, and the heat duty 

is 172,581,480 [kJ/batch]. The composition does not change and can be viewed in table 11. 

<P><TABLE class="wikitable" style="width:60%;"><CAPTION><B>Table 11:</B> Composition and conditions for E3  </CAPTION><TBODY><TR><TD>S22: Waste</TD><TD> S23: Waste </TD></TR><TR><TD>Total mass [kg]</TD><TD> 80.27 </TD><TD>80.27 </TD></TR><TR><TD>Temperature [Â°C]</TD><TD> 121 </TD><TD>99 </TD></TR><TR><TD>Pressure [bar]</TD><TD> 2 </TD><TD>2</TD></TR><TR><TD>WT% Dry cells </TD><TD>5.12 </TD><TD>5.12 </TD></TR><TR><TD>WT% H<SUB>2</SUB>O</TD><TD>89.98</TD><TD> 89.98 </TD></TR><TR><TD>WT% NH<SUB>4</SUB>Cl</TD><TD>0.16 </TD><TD>0.16 </TD></TR><TR><TD>WT% KH<SUB>2</SUB>PO<SUB>4</SUB></TD><TD>0.52 </TD><TD>0.52 </TD></TR><TR><TD>WT% MgSÂ·7 H<SUB>2</SUB>O</TD><TD>0.18</TD><TD> 0.18 </TD></TR><TR><TD>WT% CaCl<SUB>2</SUB>Â·2H<SUB>2</SUB>O</TD><TD>0.002</TD><TD> 0.002 </TD></TR><TR><TD>WT% FeSO<SUB>4</SUB></TD><TD>0.005 </TD><TD>0.005 </TD></TR><TR><TD>WT% L-arginineÂ·HCI </TD><TD>0.96 </TD><TD>0.96 </TD></TR><TR><TD>WT% TraceMetals </TD><TD>2.56 </TD><TD>2.56 </TD></TR><TR><TD>WT% Ampicilin </TD><TD>0.01 </TD><TD>0.01 </TD></TR><TR><TD>WT% NaHEPES </TD><TD>0.21 </TD><TD>0.21 </TD></TR><TR><TD>WT% NaCl </TD><TD>1.30 </TD><TD>1.30</TD></TR></TBODY></TABLE></P></DIV><DIV class="accordionTitel">C1.3: Cleavage </DIV><DIV class="pane" style="height:auto;"><DIV class="thumb tright"><DIV class="thumbinner" style="width:255px; height:650px;"><DIV class="thumbcaption">Figure 14: Cleavage of Intein</DIV></DIV></DIV>

In this step Intein selfcleaves releasing the peptide aptamer. This is achieved by flushing the 

column with 3 BV of cleavage buffer (20 mM Na-HEPES, 500 mM NaCl, 50 mM threo-1,4-Dimercapto-2,3-

butanediol (DTT)), where after the resin is left at room temperature for 16 h, therefore it is assumed that all 

buffer leaves the column as waste in this step. It has been reported, that product recovery is above 95%, therefore it is assumed that 95% will be cleav 

<SPAN class="sourceReference">ed.</SPAN>. 
<SPAN class="tooltip"><SPAN class="tooltipHeader">Reference:</SPAN>

NEB-impact
</SPAN><TABLE class="wikitable" style="width:60%;"><CAPTION><B>Table 12:</B> Composition and conditions for C1.3  </CAPTION><TBODY><TR><TD>S13: Cleavage </TD><TD> S14: Waste  </TD></TR><TR><TD>Total mass [kg] </TD><TD>3.76 </TD><TD>3.76 </TD></TR><TR><TD>Temperature [Â°C]</TD><TD> 21 </TD><TD>21 </TD></TR><TR><TD>Pressure [bar]</TD><TD> 1 </TD><TD>1 </TD></TR><TR><TD>WT% H<SUB>2</SUB>O</TD><TD>95.83 </TD><TD>95.83 </TD></TR><TR><TD>WT% NaHEPES </TD><TD>0.48 </TD><TD>0.48</TD></TR><TR><TD>WT% NaCl </TD><TD>2.92 </TD><TD>2.92 </TD></TR><TR><TD>WT% DTT </TD><TD>0.77</TD><TD> 0.77</TD></TR></TBODY></TABLE></DIV><DIV class="accordionTitel">C1.4: Elution</DIV><DIV class="pane" style="height:auto;"><DIV class="thumb tright"><DIV class="thumbinner" style="width:255px; height:680px;"><DIV class="thumbcaption"> Figure 15: Elution of peptide aptamer</DIV></DIV></DIV>
Now the product is ready to be eluted with column buffer. Since the peptide aptamers are an alternative to 

monoclonal antibodies, the concentration of the end product has been chosen by comparison of 50 

products from Sigma-Aldrich. Concentrations of the antibodies range from 0.5-2 g/L, the most common 

concentration (39 out of 50) was found to be 2 g/L, thus making this the target concentration of PASTâ€™s 

products. See pdf (<A target="_blank" href="https://static.igem.org/mediawiki/2015/0/01/SDU2015_sigma-aldrich_antibodies.pdf">Sigma-Aldrich antibodies</A>) for deta<SPAN class="sourceReference">ils</SPAN>. 
<SPAN class="tooltip"><SPAN class="tooltipHeader">Reference:</SPAN>
NEB-impact 

Pharmacia. Introduction to Expanded Bed Adsorption. 
<A target="_blank" href="http://wolfson.huji.ac.il/purification/PDF/Expanded_Bed_Absorption/PHARMACIA_IntrodEBA.pdf">(Link)</A> Accessed July 18<SUP>th</SUP> 2015

Sigma-Aldrich. <A href="http://www.sigmaaldrich.com/catalog/search?interface=All&amp;term=antibodies+monoclonal&amp;N=0+14574647&amp;mode=match+partialmax&amp;focus=product&amp;lang=en&amp;region=DK">(Link)</A> Accessed August 1<SUP>st</SUP> 2015.
</SPAN><P>


Due to the changing productions and the decision to release the broth at a predefined viscosity, 

concentrations of the product in each batch will fluctuate. Therefore the aim is to produce 2.5 g of the 

peptide aptamer per batch. The wanted concentration is reached by measuring the concentration at the 

release of the broth and adjust the elution accordingly. This determines the volume 

of the elution, the result can be viewed in table 13. Elution is performed with column buffer. If this buffer is 

not suited for storage, it can be changed by dialysis, though for now it is assumed appropr<SPAN class="sourceReference">iate</SPAN>. 
<SPAN class="tooltip"><SPAN class="tooltipHeader">Reference:</SPAN>
NEB-impact 

Pharmacia. Introduction to Expanded Bed Adsorption. 
<A target="_blank" href="http://wolfson.huji.ac.il/purification/PDF/Expanded_Bed_Absorption/PHARMACIA_IntrodEBA.pdf">(Link)</A> Accessed July 18<SUP>th</SUP> 2015]
</SPAN></P><P><TABLE class="wikitable" style="width:60%;"><CAPTION><B>Table 13:</B> Composition and conditions for C1.4  </CAPTION><TBODY><TR><TD>S15: Elution </TD><TD>  S16: product  </TD></TR><TR><TD>Total mass [kg]</TD><TD> 1.19 </TD><TD>1.19 </TD></TR><TR><TD>Temperature [Â°C]</TD><TD> 21 </TD><TD>21 </TD></TR><TR><TD>Pressure [bar] </TD><TD>1</TD><TD> 1 </TD></TR><TR><TD>WT% Peptide aptamer </TD><TD>0.20 </TD></TR><TR><TD>WT% H<SUB>2</SUB>O</TD><TD>96.60 </TD><TD>96.40 </TD></TR><TR><TD>WT% NaHEPES </TD><TD>0.48 </TD><TD>0.48 </TD></TR><TR><TD>WT% NaCl</TD><TD> 2.92 </TD><TD>2.92</TD></TR></TBODY></TABLE></P></DIV><DIV class="accordionTitel">C1.5: Regeneration</DIV><DIV class="pane" style="height:auto;"><DIV class="thumb tright"><DIV class="thumbinner" style="width:255px; height:650px;"><DIV class="thumbcaption">Figure 16: Regeneration of the column</DIV></DIV></DIV>
The last step of the product recovery is regeneration of the column, which prepares it for the next batch. It 

has been reported that the resin can be reused 4-5 times, it is assumed that 4 times is appropriate. Regeneration is 

performed by washing the bed with 3 BV of stripping solution (0.3 M Sodium hydroxide (NaOH)) and 

then leaving the bed to soak for 30 minutes. After which the column is washed with additional 7 BV of the 

stripping solution, followed with 20 BV of water. Lastly 5 BV of column buffer is app<SPAN class="sourceReference">lied</SPAN>. 
<SPAN class="tooltip"><SPAN class="tooltipHeader">Reference:</SPAN>

NEB-impact
</SPAN><P><TABLE class="wikitable" style="width:60%;"><CAPTION><B>Table 14:</B> Composition and conditions for C1.5  </CAPTION><TBODY><TR><TD>S17: Stripping</TD><TD> S18: Water </TD><TD>S19: Column buffer </TD><TD>S20: Waste </TD></TR><TR><TD>Total mass [kg] </TD><TD>11.88 </TD><TD>8.31</TD><TD> 5.94 </TD><TD>26.13  </TD></TR><TR><TD>Temperature [Â°C] </TD><TD>21 </TD><TD>21</TD><TD> 21 </TD><TD>21  </TD></TR><TR><TD>Pressure [bar] </TD><TD>1 </TD><TD>1 </TD><TD>1 </TD><TD>1 </TD></TR><TR><TD>WT% H<SUB>2</SUB>O</TD><TD>99.64</TD><TD> 100 </TD><TD>96.60 </TD><TD>99.06  </TD></TR><TR><TD>WT% NaHEPES </TD><TD>0.48</TD><TD> 0.11 </TD></TR><TR><TD>WT% NaCl </TD><TD>2.92</TD><TD> 0.66  </TD></TR><TR><TD>WT% NaOH </TD><TD>0.36</TD><TD>0.16 </TD></TR></TBODY></TABLE></P></DIV></DIV><DIV class="thumb" align="center"><DIV class="thumbinner" style="width:355px; height:180px;"><DIV class="thumbcaption">Figure 17: Timeline illustrating the entire process. </DIV></DIV></DIV></DIV><DIV class="footer "><DIV class="footerContainer"><A class="footerBtn footerShadow" id="btnFastForward"><P class="footerBtnPre">Next chapter
</P></A><A class="footerBtn footerShadow" id="btnNextChapter"><P class="footerBtnPre">Next chapter
</P></A><A class="footerBtn footerShadow" id="btnDigDeeper"><P class="footerBtnPre">Dig deeper
</P></A><A class="footerBtn footerShadow" id="btnTheEnd" href="http://www.igem.org" target="_blank"><P class="footerBtnPre">End of tour
</P><P class="footerBtnHeader" style="text-transform: none !important;">Want more? Go to iGEM.org!</P><P class="footerBtnText">
If you want to learn more about Synthetic Biology you should visit iGEM's homepage, which contains loads on the subject. You can even visit other teams' wikis and take a look at what they accomplished. Or maybe join a team yourself?</P></A></DIV></DIV></DIV></DIV>&lt;&quot;Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum.&quot;&gt;</DIV></DIV></DIV></DIV></DIV></BODY></HTML>